David N Garvey

US Patent:

6706724, Mar 16, 2004

Filed:

Dec 21, 2001

Appl. No.:

10/024046

Inventors:

Subhash P. Khanapure - Clinton MA
David S. Garvey - Dover MA
Richard A. Earl - Westford MA
Maiko Ezawa - Acton MA
Xinqin Fang - Lexington MA
Ricky D. Gaston - Malden MA

Assignee:

NitroMed, Inc. - Bedford MA

International Classification:

A61K 31435

US Classification:

514277, 514336, 514340, 514342, 514365, 514374, 514443, 514469, 546 1, 546114, 546115, 546208, 548146, 548152, 548153, 548217, 549229, 549396, 549398, 549430, 549462, 549469, 549472

Abstract:

The invention describes novel substituted aryl compounds that are cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or, optionally, at least one therapeutic agent, such as, steroids, nonsterodal antiinflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B (LTB ) receptor antagonists, leukotriene A (LTA ) hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitors, H antagonists, antineoplastic agents, antiplatelet agents, thrombin inhibitors, thromboxane inhibitors, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, inhibitors, proton pump inhibitors, isoprostane inhibitors, and mixtures thereof. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated.

US Patent:

6825185, Nov 30, 2004

Filed:

Dec 10, 2003

Appl. No.:

10/730979

Inventors:

Subhash P. Khanapure - Clinton MA
David S. Garvey - Dover MA
Richard A. Earl - Westford MA
Maiko Ezawa - Acton MA
Xinqin Fang - Lexington MA
Ricky D. Gaston - Malden MA

Assignee:

NitroMed, Inc. - Lexington MA

International Classification:

A61K 3133

US Classification:

514183, 514277, 51425205, 514256, 514365, 514367, 514374, 514375, 514461, 514469, 544224, 544242, 546 1

Abstract:

The invention describes novel substituted aryl compounds that are cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or, optionally, at least one therapeutic agent, such as, steroids, nonsterodal antiinflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B (LTB ) receptor antagonists, leukotriene A (LTA ) hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitors, H antagonists, antineoplastic agents, antiplatelet agents, thrombin inhibitors, thromboxane inhibitors, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, inhibitors, proton pump inhibitors, isoprostane inhibitors, and mixtures thereof. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated.

US Patent:

7163958, Jan 16, 2007

Filed:

Jul 3, 2003

Appl. No.:

10/612014

Inventors:

Richard A. Earl - Westford MA, US
Maiko Ezawa - Acton MA, US
Xinqin Fang - Lexington MA, US
David S. Garvey - Dover MA, US
Ricky D. Gaston - Malden MA, US
Subhash P. Khanapure - Clinton MA, US
L. Gordon Letts - Dover MA, US
Chia-En Lin - Burlington MA, US
Ramani R. Ranatunge - Lexington MA, US
Stewart K. Richardson - Tolland CT, US
Joseph D. Schroeder - Minneapolis MN, US
Cheri A. Stevenson - Haverhill MA, US

Assignee:

NitroMed Inc. - Lexington MA

International Classification:

A61K 31/21
C07C 203/04

US Classification:

514509, 558482

Abstract:

The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.

US Patent:

7754772, Jul 13, 2010

Filed:

May 23, 2005

Appl. No.:

11/134358

Inventors:

Richard A. Earl - Westford MA, US
Maiko Ezawa - Acton MA, US
Xinqin Fang - Lexington MA, US
David S. Garvey - Dover MA, US
Ricky D. Gaston - Malden MA, US
Subhash P. Khanapure - Clinton MA, US
L. Gordon Letts - Dover MA, US
Chia-En Lin - Burlington MA, US
Ramani R. Ranatunge - Lexington MA, US
Stewart K. Richardson - Tolland CT, US
Joseph D. Schroeder - Minneapolis MN, US
Cheri A. Stevenson - Haverhill MA, US

Assignee:

NicOx, S.A.

International Classification:

A61K 31/135
C07C 203/04

US Classification:

514658, 558484

Abstract:

The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.

US Patent:

7883714, Feb 8, 2011

Filed:

Dec 11, 2009

Appl. No.:

12/636306

Inventors:

Richard A. Earl - Westford MA, US
Maiko Ezawa - Acton MA, US
Xinqin Fang - Lexington MA, US
David S. Garvey - Dover MA, US
Ricky D. Gaston - Malden MA, US
Subhash P. Khanapure - Clinton MA, US
L. Gordon Letts - Dover MA, US
Chia-En Lin - Concord MA, US
Ramani R. Ranatunge - Lexington MA, US
Stewart K. Richardson - Tolland CT, US
Joseph D. Schroeder - Minneapolis MN, US
Cheri A. Stevenson - Haverhill MA, US

Assignee:

NicOx S.A.

International Classification:

A61K 9/00
A61K 31/21
C07C 203/04

US Classification:

424400, 514509, 514510, 558480, 558482

Abstract:

The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.

US Patent:

8088762, Jan 3, 2012

Filed:

Dec 11, 2009

Appl. No.:

12/636316

Inventors:

Richard A. Earl - Westford MA, US
Maiko Ezawa - Acton MA, US
Xinqin Fang - Lexington MA, US
David S. Garvey - Dover MA, US
Ricky D. Gaston - Malden MA, US
Subhash P. Khanapure - Clinton MA, US
L. Gordon Letts - Dover MA, US
Chia-En Lin - Concord MA, US
Ramani R. Ranatunge - Lexington MA, US
Stewart K. Richardson - Tolland CT, US
Joseph D. Schroeder - Minneapolis MN, US
Cheri A. Stevenson - Haverhill MA, US

Assignee:

NiCox S.A. - Sophia Antipolis

International Classification:

A61K 31/54
A61K 31/44
A61K 31/425
C07D 498/02
C07D 295/02
C07D 333/22

US Classification:

5142248, 514300, 514302, 514365, 544386, 548224, 549 72

Abstract:

The invention describes novel nitrosated nonsteroidal anti-inflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.

US Patent:

8222277, Jul 17, 2012

Filed:

Dec 28, 2010

Appl. No.:

12/980077

Inventors:

Richard A. Earl - Westford MA, US
Maiko Ezawa - Acton MA, US
Xinqin Fang - Lexington MA, US
David S. Garvey - Dover MA, US
Ricky D. Gaston - Malden MA, US
Subhash P. Khanapure - Clinton MA, US
L. Gordon Letts - Dover MA, US
Chia-En Lin - Concord MA, US
Ramani R. Ranatunge - Lexington MA, US
Stewart K. Richardson - Tolland CT, US
Joseph D. Schroeder - Minneapolis MN, US
Cheri A. Stevenson - Haverhill MA, US

Assignee:

NiCox S.A. - Sophia Antipolis

International Classification:

A61K 31/445
A61K 31/54
A61K 31/44
A61K 31/425
A61K 31/42
A61K 31/415
A61K 31/335
A61K 31/215
A61K 31/12

US Classification:

514327, 5142262, 514291, 514365, 514374, 514375, 514378, 514393, 514450, 514539, 514676

Abstract:

The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders comprising administration of novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent.

US Patent:

8304409, Nov 6, 2012

Filed:

Dec 11, 2009

Appl. No.:

12/636329

Inventors:

Richard A. Earl - Westford MA, US
Maiko Ezawa - Acton MA, US
Xinqin Fang - Lexington MA, US
David S. Garvey - Dover MA, US
Ricky D. Gaston - Malden MA, US
Subhash P. Khanapure - Clinton MA, US
L. Gordon Letts - Dover MA, US
Chia-En Lin - Concord MA, US
Ramani R. Ranatunge - Lexington MA, US
Stewart K. Richardson - Tolland CT, US
Joseph D. Schroeder - Minneapolis MN, US
Cheri A. Stevenson - Haverhill MA, US

Assignee:

Nicox S.A.

International Classification:

A61K 31/54
A61K 31/44
A61K 31/445
A61K 31/425
A61K 31/42
A61K 31/415
A61K 31/335
A61K 31/24
A61K 31/12

US Classification:

5142262, 514291, 514327, 514365, 514374, 514375, 514378, 514393, 514450, 514539, 514676

Abstract:

The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.